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ABSTRACT
Introduction Left untreated, sexually transmitted and
genital infections (henceforth STIs) in pregnancy can lead
to serious adverse outcomes for mother and child. Papua
New Guinea (PNG) has among the highest prevalence of
curable STIs including syphilis, chlamydia, gonorrhoea,
trichomoniasis and bacterial vaginosis, and high neonatal
mortality rates. Diagnosis and treatment of these STIs
in PNG rely on syndromic management. Advances in
STI diagnostics through point-of-care (PoC) testing
using GeneXpert technology hold promise for resource-
constrained countries such as PNG. This paper describes
the planned economic evaluation of a cluster-randomised
cross-over trial comparing antenatal PoC testing and
immediate treatment of curable STIs with standard
antenatal care in two provinces in PNG.
Methods and analysis Cost-effectiveness of the PoC
intervention compared with standard antenatal care will be
assessed prospectively over the trial period (2017–2021)
from societal and provider perspectives. Incremental
cost-effectiveness ratios will be calculated for the primary
health outcome, a composite measure of the proportion of
either preterm birth and/or low birth weight; for life years
saved; for disability-adjusted life years averted; and for
non-health benefits (financial risk protection and improved
health equity). Scenario analyses will be conducted to
identify scale-up options, and budget impact analysis
will be undertaken to understand short-term financial
impacts of intervention adoption on the national budget.
Deterministic and probabilistic sensitivity analysis will be
conducted to account for uncertainty in key model inputs.
Ethics and dissemination This study has ethical
approval from the Institutional Review Board of the PNG
Institute of Medical Research; the Medical Research

Strengths and limitations of this study
►► This protocol will assist in designing economic

evaluations for similar complex public health interventions, especially those that seek to capture both
health and non-health impacts of point-of-care testing for sexually transmitted infections in low- and
middle-income countries (LMICs).
►► This protocol follows the Consolidated Health Economic
Evaluation Reporting Standards, and guidelines from
the Global Health Cost Consortium to design and report economic evaluations nested in a randomised
controlled trial and will include individual-level patient
cost and health service use data.

Advisory Committee of the PNG National Department of
Health; the Human Research Ethics Committee of the
University of New South Wales; and the Research Ethics
Committee of the London School of Hygiene and Tropical
Medicine. Findings will be disseminated through national
stakeholder meetings, conferences, peer-reviewed
publications and policy briefs.
Trial registration number ISRCTN37134032.

INTRODUCTION
In 2017, it was estimated that every day, globally, more than 1 million people acquire any
of the four common curable sexually transmitted infections: chlamydia, gonorrhoea,
syphilis and trichomoniasis.1–3 Left untreated,
sexually transmitted and genital infections
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Strengths and limitations of this study
►► The planned budget impact and affordability analyses will contribute

to the understanding of fiscal space for investments in maternal and
child health at provincial and country levels.
►► This analysis builds on conventional cost-effectiveness analysis by including non-health benefits such as financial risk protection that are
key criteria for equitable resource allocation, and the design of health
benefit packages in many LMICs including Papua New Guinea.
►► The planned analyses for the base case scenario adopt only a 12-month
time horizon but we propose to model the costs and benefits over the
lifetime of mother and their babies using published data.

such as bacterial vaginosis (henceforth, referred to as
STIs) are associated with adverse pregnancy and birth
outcomes including spontaneous abortion, miscarriage,
stillbirth, pre-term birth, low birth weight, postpartum
endometritis, premature rupture of membranes, and
various sequelae in newborn infants owing to mother-to-
child transmission such as ophthalmia neonatorum.4–13
In Papua New Guinea (PNG), prevalence of STIs is
high in the general population and among pregnant
women.14 Clinical studies in PNG show that around 50%
of all pregnant women test positive for one or more STIs
at their first antenatal care (ANC) visit,6 15 with gonorrhoea, chlamydia, trichomoniasis and bacterial vaginosis
most commonly diagnosed.5 6 15 16 There is evidence from
resource-constrained settings to suggest that increased
screening for HIV and syphilis in pregnancy is correlated
with a reduction in perinatal and infant morbidity and
mortality.17 18 In this high-
burden and low-
resource
setting, poor access to ANC leads to missed opportunities
for early diagnosis and clinical intervention.19
Traditional STI diagnosis for infections other than HIV
and syphilis relies on microscopy, culture, and/or serology
that require technical resources and expertise that may
not be readily available in all low- and middle-income
country (LMIC) settings.20 21 The long waiting period for
results also deters some people from returning to collect
their results.22 In settings where laboratory services are
not available, syndromic management, which relies on
clinical presentation, is most often used to inform treatment decisions. This strategy fails to accurately identify
causative pathogens or detect asymptomatic infections,
and consequently leads to negligible impact on health
outcomes.22 23 The development of accurate rapid diagnostic tests for HIV and syphilis used at point-
of-
care
(PoC) has improved their detection, testing coverage
and the number of patients accurately diagnosed and
treated.24–26 From an equity standpoint, PoC testing has
been shown to improve access to testing and treatment
particularly among remote and hard-
to-
reach populations.24 27 However, the success of HIV and syphilis PoC
diagnosis is yet to be replicated for other common curable
STIs, including chlamydia and gonorrhoea.28–32
The Women and Newborn Trial of Antenatal Interventions and Management (WANTAIM) study is the
2

first randomised trial to evaluate the effectiveness and
cost-effectiveness of PoC STI testing and treatment to
improve birth outcomes in high-burden settings.33 This
paper aims to describe the rationale and methodological
approach for the economic evaluation of this large-scale
trial involving 4600 pregnant women in PNG.
In recent years, the evidence base for the cost and cost-
effectiveness of PoC testing for STIs in pregnancy has
grown, including in LMICs. A recent systematic review34
identified that the bulk of these studies was conducted in
Africa or Latin and South America,35–49 with no studies
undertaken in East Asia or the Pacific. Most of the studies
investigated the cost and cost-effectiveness of PoC testing
for syphilis in pregnancy compared with no screening,
syndromic management or onsite laboratory testing.
Only one study evaluated testing for HIV and testing and
treatment for syphilis,46 another for chlamydia,39 and
none evaluated testing for gonorrhoea, trichomoniasis
or bacterial vaginosis. Few studies evaluated the costs
and cost-effectiveness of the test and treatment package
combined. Despite widespread acknowledgement of the
high out-of-pocket costs incurred by women and their
families in accessing testing and treatment in many
LMICs, the studies in the review were largely conducted
from the provider perspective.35 38–41 43 47–49 Further,
none of the studies presented estimates of affordability
or budget impact and none analysed non-health-related
outcomes such as equity or financial risk protection.50
STUDY SETTING
Papua New Guinea
In PNG, pregnant women and their infants experience
a high burden of adverse health outcomes, with PNG
recording one of the highest maternal mortality ratios
and neonatal mortality rates in the world: 584 per 100 000
and 25 per 1000 live births, respectively, compared with
global figures of 209 and 18.51 52 In 2012, 20% of births in
PNG were preterm birth and/or low birth weight, both
key contributors to neonatal mortality.53
Pregnant women in PNG experience a high burden
of curable STIs. Findings from a country-
wide bio-
behavioural survey of STIs in pregnancy indicated that
the prevalence of chlamydia was 23%, gonorrhoea 14%
and trichomoniasis 22%, with 44% of women having at
least one of these infections.5 Another study evaluating
the feasibility of a novel PoC testing and treatment
strategy for STIs in PNG found that 54% of women had
one or more of chlamydia, gonorrhoea, trichomoniasis
or bacterial vaginosis, and the prevalence rates of each of
these STIs were 19%, 11%, 38% and 18%, respectively.20
Similar prevalence rates of STIs were observed in a study
of malaria prevention in pregnancy.6 In these studies,
between 65% and 80% of infections among pregnant
women were asymptomatic indicating the need for more
accurate diagnosis at PoC.
In PNG, national guidelines for ANC state that PoC
testing and treatment for HIV and syphilis should be
Batura N, et al. BMJ Open 2021;11:e046308. doi:10.1136/bmjopen-2020-046308
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undertaken for all pregnant women at the first ANC clinic
visit. For women who test positive, treatment according
to national guidelines is offered along with partner
testing.54 However, despite the high prevalence of chlamydia, gonorrhoea, trichomoniasis and bacterial vaginosis among pregnant women, detection and treatment
rely on syndromic management according to national
guidelines.54
Health services in PNG
In PNG, health services are organised into seven levels
of care. Levels 1–4 offer primary care at community aid
posts, subhealth centres, health centres, and rural/district
hospitals. The majority of level 1–3 facilities are managed
and staffed by health extension officers, nursing officers,
midwives and community health workers; level 4 facilities, that is, rural/district hospitals usually have a doctor
on staff. Population coverage varies from about 5000 to
20 000 per facility and the average distance travelled to
reach a facility is 7–8 km. Secondary level care is provided
at provincial/regional/national referral hospitals (levels
5–7), which cover an average population of 200 000 and
300 000 in one or more provinces.55 56 Health workforce
distribution is suboptimal, with 0.5 physicians per 10 000
population,57 compared with the WHO recommended
ratio of 10 physicians per 10 000 population.58 Healthcare is predominantly provided by public health facilities that are either financed and operated by the PNG
government or by churches with financial support from
the government.59
The WANTAIM trial
WANTAIM aims to test the effectiveness of antenatal PoC
testing and treatment for STIs to improve maternal and
newborn outcomes in PNG. WANTAIM is being implemented in two provinces in PNG—Madang and East New
Britain. Data collection continues despite the challenges
of the COVID-19 pandemic, and the trial is due to finish
in late 2021.33
WANTAIM is a cluster-randomised cross-over trial and
the unit of randomisation is a primary healthcare centre
and its catchment area. Ten geographically distinct clusters have been assigned in a 1:1 ratio to intervention and
control arms in the first phase of the trial. The end of
the first phase of the trial is followed by a short washout
period of 2–3 months, at the end of which each cluster
will cross over to participate in the alternative trial arm
in the second phase. The study participants are women
attending their first ANC visit, aged over 16 years and
less than 26 weeks’ gestation (assessed by ultrasound)
(n=4600). Newborn infants are followed up within 72
hours of birth.
Pregnant women recruited into the study receive
routine ANC as per PNG national guidelines including
sulfadoxine/pyrimethamine for malaria prevention;
iron and folate supplementation; tetanus toxoid immunisation; HIV and syphilis screening (and treatment
if required). Women in the control arm receive STI
Batura N, et al. BMJ Open 2021;11:e046308. doi:10.1136/bmjopen-2020-046308

syndromic management if they report symptoms of a
genital infection (abdominal pain, discharge). They also
provide a urine sample for diagnostic testing on GeneXpert in the study laboratory. If positive for STI at their
last test, they receive treatment during the first postnatal
visit. Women in the intervention arm of the trial provide
a self-collected vaginal specimen for PoC STI testing, and
same-day treatment as necessary, at the following time
points:
►► At enrolment (<26 weeks’ gestation).
►► One month after trial enrolment.
►► At 34–36 weeks’ antenatal follow-up.
The primary outcome of the trial is a composite
measure of two events, the proportion of women and
their newborn infants in each trial arm who experience
either a preterm birth (<37 weeks’ gestation) and/or low
birth weight (<2500 g).
The study has ethical approval from the Institutional
Review Board (IRB) of the PNG Institute of Medical
Research (IRB number 1608); the Medical Research Advisory Committee (MRAC) of the PNG National Department of Health (MRAC number 16.24); the Human
Research Ethics Committee (HREC) of the University
of New South Wales (HREC number 16708); and the
Research Ethics Committee (REC) of the London School
of Hygiene and Tropical Medicine (REC number 12009).
A full description of the WANTAIM intervention and
trial design is described elsewhere.33 The purpose of this
paper is to fully describe the methods for the economic
evaluation of the trial.
AIMS AND OBJECTIVES
The economic evaluation aims to assess the cost-
effectiveness and affordability of PoC testing and treatment of curable STIs in pregnancy compared with
standard care from a provider and societal perspective.
The specific objectives of the economic evaluation are to:
1. Estimate total financial and economic costs of the PoC
STI intervention.
2. Model incremental cost-effectiveness of the intervention compared with standard care.
3. Extend the incremental cost-
effectiveness analysis
(CEA) to include equity-related measures of impact.
4. Conduct a budget impact analysis to assess the affordability of implementing the intervention at the national level or in target areas/populations.
These planned analyses will adhere to the Consolidated Health Economic Evaluation Reporting Standards
and established guidelines from the Global Health Cost
Consortium for conducting and reporting economic evaluation for global health trials.60 61
METHODS: ECONOMIC EVALUATION OF THE WANTAIM TRIAL
Costing data
Cost data collection is guided by the perspective adopted
for the economic evaluation. For WANTAIM, direct and
3
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Table 1 Cost category and data sources
Description

Type of cost

Data sources

Sample size

 Costs of
implementing
WANTAIM

Direct

Project accounts
of implementing
agencies

N/A

 Cost of
providing ANC
services

Direct

Health facilities

10 health
facilities

Provider costs

Indirect
 Cost of
increased
workload of
facility staff
associated with
PoC testing
and treatment

Patient pathway
20–30
and health worker
observation
data collected
as part of the
health facility
assessment

Participant costs
 Costs of care- Direct and
indirect
seeking

Participant case
report forms

4600

ANC, antenatal care; N/A, not applicable; PoC, point-of-care;
WANTAIM, Women and Newborn Trial of Antenatal Interventions and
Management.

indirect costs will be collected from the provider perspective and societal perspective—the latter including any
costs incurred by pregnant women and their families. The
different cost categories and data sources are summarised
in table 1. A combination of top-down and bottom-up
costing approaches will be used60 and the time horizon
for the main trial-based economic evaluation will be 12
months.
Provider costs are incurred by the institutions implementing the PoC testing intervention across the start-up,
implementation and monitoring phases of the trial.
The cost data will be sourced from financial records,
programme documents and consultation with project
staff. A step-
down costing methodology will be used,
whereby costs from project accounts are entered into
a customised tool created in Microsoft Excel, which is
adapted each year to reflect the changing cost structure of
the trial during the start-up and implementation phases.
Financial costs will be converted to economic costs,
that is, any donated goods or volunteer time that do not
appear in the programme accounting data will be added
to the cost sheets and assigned a current market value.62 63
Key informant interviews with programme leads will assist
in identifying donated or subsidised items and in allocating joint costs between programme components. The
allocation of joint staff costs will be informed by monthly
staff timesheets. Research costs will not be included in the
CEA. However, start-up costs will be reported and differentiated from implementation costs to enable decision-
makers to gauge the costs associated with the initial
activities and expenditures necessary to develop PoC
testing and integration with standard ANC.64
Provider (treatment) costs are incurred by provincial
health authorities, who manage ANC, delivery and
postnatal visits; and church health services, non-
state
4

providers who access a mix of government and institutional funds. Primary data on the average unit cost of care
will be collected from all health facilities participating
in the WANTAIM trial. A simple cost-capture form has
been developed for facility data collection adapted from
other costing studies led by members of this team.65 66
Data from this form will be used to complement existing
data from centre reports, patients’ records and published
national reports relating to ANC, labour and birth care,
and postnatal care visits. Costs of services provided will
also be calculated using a step-down approach.67
Participant (treatment) costs are the direct and indirect
costs of healthcare seeking incurred by women and
their families such as medical costs, transport costs and
the opportunity costs in terms of lost productivity due to
care-seeking visits. These will be estimated for standard
treatment episodes in the control arms and for treatment
episodes in the intervention arm to gauge changes in out-
of-pocket costs of care-seeking and time dedicated to care-
seeking for participants. Data on the direct and indirect
costs incurred by participants are being collected from
all trial participants (n=4600) in both arms of the trial at
enrolment and three follow-up visits through participant
case report forms (CRFs). The participant cost data will
be summed and analysed as cross-sectional data to gauge
the economic burden borne by participants and their
households that is alleviated due to PoC testing and treatment of STIs in pregnancy.
Health service use
Health service utilisation for all trial participants in the
intervention and control arms will be estimated using
data collected via a take-home aide memoire and participant CRFs. The aide memoire is provided to all participants at recruitment, who use this tool to make notes
about the facility visits that they make or attend between
the WANTAIM follow-up visits. The aide memoire also
allows them to make notes about any costs associated with
those visits. At the WANTAIM follow-up visits, these notes
serve as prompts for questions about service utilisation
and costs of care-seeking, which are recorded in the CRFs.
Proposed analyses
Cost and CEAs
A base case analysis will be undertaken alongside the
trial to estimate the cost-effectiveness of the intervention
compared with standard care as implemented. The base
case will include all start-up costs and implementation
costs. Costs will be presented in current prices in PNG
kina and international dollars (INT$). All costs will be
adjusted for inflation using the Consumer Price Index
for PNG and will be converted to 2021 INT$ using the
2021 Purchasing Power Parity conversion factor for PNG.
Costs and outcomes will be converted to present values
using an annual discount rate of 3% in the base case, and
annual rates of 0%, 6% and 9% in sensitivity analyses.
For the base case analysis, results will be presented
in terms of total financial and economic costs of the
Batura N, et al. BMJ Open 2021;11:e046308. doi:10.1136/bmjopen-2020-046308
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intervention and incremental cost-
effectiveness ratios
(ICERs) for the primary outcome, that is, the proportion of women and their newborns who experience
either preterm birth and/or low birth weight. ICERs will
be calculated as the arithmetic mean difference in cost
between the intervention and control arms, divided by
the arithmetic mean difference in effect. To maximise
comparability with other trials, ICERs will also be reported
in terms of cost per life year saved and cost per disability-
adjusted life year (DALY) averted (see the Modelling
section for details).
A descriptive analysis of missing data will be undertaken
to inform the base case assumption regarding the missing
data mechanism (the probability that missing data are
independent or not on the observed or unobserved
values). Appropriate methods will be used to handle
the missing data, which may include mean imputation,
multiple imputations, available case analysis, inverse
probability weighting or likelihood methods.68 Sensitivity
analyses will be conducted as appropriate.
The data on costs and outcomes for the period of trial
follow-up will be at the individual level, allowing evalueffectiveness estimates
ation of uncertainty of the cost-
using non-parametric bootstrapping.69 Cost-effectiveness
acceptability curves (CACs) will be generated to further
describe uncertainty around the cost estimates.70 CACs
indicate the proportion of the estimates produced by
bootstrapping that would be ‘acceptable’ below a range
of willingness-to-pay thresholds, where willingness to pay
is the value placed on an additional pregnant woman
appropriately tested for STIs in pregnancy. Sensitivity
analyses will take into account the uncertainty in key
parameters that may have been affected by the COVID-19
pandemic, such as staff or drug costs.
Modelling
The base case analysis will have a time horizon of up to 12
months. If the intervention demonstrates clinical effectiveness over that period, we will employ a cohort decision analytical model to examine the cost-effectiveness
of the intervention over a newborn’s lifetime. A Markov
model will be used to estimate the long-term health benefits, healthcare costs and cost-effectiveness of the PoC
intervention compared with standard care, drawing on
results of the WANTAIM trial and available published
data. The point of entry into the model will be ‘tested for
STIs’. There are two possible states for women: infected
or uninfected. Women identified as infected and then
treated may recover and stay healthy, become re-infected
or die. Health outcomes will therefore depend on treatment compliance and include live birth without infection
(healthy infant), live birth with infection, preterm and/
or low birth weight, and neonatal death. The model will
be used to project differences between the intervention
and control arms in life years saved, DALYs averted and
lifetime healthcare costs. Sensitivity analyses will also be
conducted within this model.
Batura N, et al. BMJ Open 2021;11:e046308. doi:10.1136/bmjopen-2020-046308

Equity impact of the intervention
The equity impact of the intervention will be investigated by conducting an extended CEA (E-
CEA). The
E-CEA broadens the scope of the CEA by incorporating
health equity and financial protection considerations for
the most vulnerable sections of the population that are
likely to have the highest need.71 This will be done across
three domains: by exploring improving health gains,
with particular reference to the poorest socioeconomic
group; reduction in the out-of-pocket expenses faced by
households seeking care; and improved financial protection or reducing the number of households that sink into
poverty due to catastrophic health spending.72 For the
E-CEA, provider and participant cost data (table 1) will
be synthesised with data on service utilisation that will
be collected via participant CRFs that are completed at
enrolment into the trial and at three follow-up trial visits.
All results will be presented by socioeconomic quintiles.
Given that socioeconomic groups may not differ greatly
within clusters, a Multidimensional Poverty Index (MDPI)
will be derived from socioeconomic and income data
collected from all trial participants at enrolment. The
use of an MDPI provides a more nuanced understanding
of socioeconomic status of households as it takes monetary and non-monetary dimensions of deprivation into
account.73 This enables the differentiation between population groups who may all be relatively poor in monetary
dimensions such as income or asset ownership.74 Thus,
the consideration of other non-monetary attributes (eg,
housing) allows us to distinguish between households
that are homogeneously asset or cash poor in this study
setting.74
Scale-up and budget impact analysis
The costs and cost-effectiveness of the intervention will
also be considered in a scale-up scenario, in which any
start-up costs will be excluded as they are considered sunk
costs.75 The budget impact of the scale-up scenario will
be explored by an analysis of fiscal space for programme
delivery using a generalised fiscal space assessment
method76 77 and probabilistic analyses to determine a set
of cost-effectiveness thresholds.70 78
Patient and public involvement
WANTAIM trial participants were involved in providing
data for the study.

DISCUSSION
To our knowledge, this paper is the first protocol for the
economic evaluation of PoC STI testing and treatment
in pregnancy in an LMIC setting. The proposed analyses
aim to assess the cost-effectiveness of the intervention as
well as its affordability and equity impact. The analyses
will adhere to international guidelines for conducting
and reporting economic evaluation studies and provide
transparency in how they are conducted. The findings of
the economic evaluation will provide decision-makers in
5
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PNG and similar settings evidence on the relative value for
money of this intervention and the likely level of investment required for implementation at scale. The findings
of this study will be disseminated through national stakeholder meetings, conferences, peer-reviewed publications
and policy briefs.
Dissemination
The findings of the economic evaluation of the WANTAIM
trial will be disseminated to academic and policymaking
communities, and the wider public, in peer-reviewed journals, and presented at relevant conferences in PNG and
globally.
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